@article {Prefontaine169, author = {M. Prefontaine and G. J. O{\textquoteright}Connell and E. Ryan and K. J. Murphy}, title = {Is there a role for CA-125 in monitoring patients with early endometrial cancer?}, volume = {1}, number = {4}, pages = {169--172}, year = {1991}, doi = {10.1046/j.1525-1438.1991.01040169.x}, publisher = {BMJ Specialist Journals}, abstract = {Elevated CA-125 levels have been reported in some women with endometrial carcinoma. Current follow-up policy for these patients does not involve the use of tumor markers. CA-125 measurements were performed in 28 patients with a diagnosis of endometrial cancer, 14 clinically free of disease and 14 with known disease. Based on the sensitivity (0.64) and specificity (0.93) observed we constructed a model to estimate the predictive value of the assay as a marker in the follow-up of patients who have completed treatment. This model would involve a CA-125 assay every six months for five years in 100 patients with stage I and II disease. Despite the high statistical correlation between the clinical status of the patient and the CA-125 value observed in our study, the positive predictive value would be approximately 24\% in such a follow-up protocol where a low prevalence of recurrent malignancy is expected.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/1/4/169}, eprint = {https://ijgc.bmj.com/content/1/4/169.full.pdf}, journal = {International Journal of Gynecologic Cancer} }